Novartis Pharma Obtains Additional Approval for Osteoclastic Inhibitor Zometa.Tokyo, Japan, Apr 21, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Novartis Pharma announced on April 20 that it had obtained additional approval for Zometa Injection 4mg, its proprietary osteoclastic inhibitor, from the Ministry of Health, Labor and Welfare. The agent is currently available for the treatment of bone metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases 1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to in multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility (MM) and solid tumor tumor: see neoplasm. . Zometa, a bisphosphonate agent, is currently available in over 90 countries worldwide. This is the first agent for bone lesion in MM and solid tumor that has been approved in Japan. Novartis Phama plans to co-promote the agent with Nippon Kayaku. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion